ECSP066529A - Derivados de tetrazol y métodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo - Google Patents
Derivados de tetrazol y métodos para el tratamiento con los mismos de trastornos relacionados con el metabolismoInfo
- Publication number
- ECSP066529A ECSP066529A EC2006006529A ECSP066529A ECSP066529A EC SP066529 A ECSP066529 A EC SP066529A EC 2006006529 A EC2006006529 A EC 2006006529A EC SP066529 A ECSP066529 A EC SP066529A EC SP066529 A ECSP066529 A EC SP066529A
- Authority
- EC
- Ecuador
- Prior art keywords
- present
- inhibitors
- compounds
- metabolism
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a ciertos derivados de tetrazol de Fórmula (I), y sus sales aceptables para uso farmacéutico, los cuales exhiben propiedades farmacológicas útiles, por ejemplo como agonistas para el receptor RUP25. También la presente invención provee composiciones farmacéuticas que contienen compuestos de la invención, y métodos para utilizar los compuestos y composiciones de la invención en el tratamiento de trastornos relacionados con el metabolismo, que incluyen dislipidemia, aterosclerosis, enfermedad cardiaca coronaria, resistencia a la insulina, diabetes tipo 2, Síndrome-X y similares. Además, la presente invención provee el uso de los compuestos de la invención en combinación con otros agentes activos tales como los pertenecientes a la clase de inhibidores de la a-glucosidasa, inhibidores de la aldosa reductasa, biguanidas, inhibidores de la HMG-CoA reductasa, inhibidores de la síntesis del escualeno, fibratos, intensificadores del catabolismo de las LDL, inhibidores de la enzima convertidora de angiotensina (ACE), intensificadores de la secreción de insulina y similares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51623803P | 2003-10-31 | 2003-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066529A true ECSP066529A (es) | 2006-10-10 |
Family
ID=34572875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006529A ECSP066529A (es) | 2003-10-31 | 2006-04-28 | Derivados de tetrazol y métodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8637555B2 (es) |
| EP (2) | EP1683794A1 (es) |
| JP (2) | JP4533898B2 (es) |
| KR (1) | KR100850591B1 (es) |
| CN (1) | CN1867562B (es) |
| AR (1) | AR046611A1 (es) |
| AT (1) | ATE328880T1 (es) |
| AU (1) | AU2004287861B2 (es) |
| BR (1) | BRPI0415631A (es) |
| CA (1) | CA2539985C (es) |
| CO (1) | CO5690551A2 (es) |
| CR (1) | CR8270A (es) |
| CY (1) | CY1105479T1 (es) |
| DE (1) | DE602004001134T2 (es) |
| DK (1) | DK1599469T3 (es) |
| EA (1) | EA011484B1 (es) |
| EC (1) | ECSP066529A (es) |
| ES (1) | ES2267077T3 (es) |
| GE (1) | GEP20094801B (es) |
| HR (1) | HRP20060286T3 (es) |
| IL (1) | IL174042A0 (es) |
| IS (1) | IS2372B (es) |
| MA (1) | MA28171A1 (es) |
| MX (1) | MXPA06004556A (es) |
| MY (1) | MY140410A (es) |
| NO (1) | NO20062509L (es) |
| NZ (1) | NZ546285A (es) |
| PE (1) | PE20050483A1 (es) |
| PL (1) | PL1599469T3 (es) |
| PT (1) | PT1599469E (es) |
| RS (1) | RS20060290A (es) |
| SI (1) | SI1599469T1 (es) |
| TN (1) | TNSN06150A1 (es) |
| TW (1) | TWI258478B (es) |
| UA (1) | UA86783C2 (es) |
| WO (1) | WO2005044816A1 (es) |
| ZA (2) | ZA200603419B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603585A2 (en) | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| JP2007512346A (ja) * | 2003-11-21 | 2007-05-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ４−オキソ−４，５−ジヒドロ−フラン−２−カルボン酸誘導体およびその代謝関連障害の処置方法 |
| US20070244107A1 (en) * | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| AU2005305086A1 (en) * | 2004-11-05 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| WO2006114581A1 (en) * | 2005-04-28 | 2006-11-02 | Merck Sharp & Dohme Limited | A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles |
| CA2611552A1 (en) | 2005-06-28 | 2007-01-04 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| EP3760629A1 (en) | 2013-02-21 | 2021-01-06 | Adverio Pharma GmbH | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
| JP6453216B2 (ja) * | 2013-07-23 | 2019-01-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ縮合環化合物 |
| CN103755637A (zh) * | 2013-12-26 | 2014-04-30 | 平湖优康药物研发有限公司 | 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺 |
| US12086719B2 (en) * | 2019-10-11 | 2024-09-10 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02178263A (ja) * | 1988-12-27 | 1990-07-11 | Kaken Pharmaceut Co Ltd | アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤 |
| US5134155A (en) | 1991-08-08 | 1992-07-28 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors |
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| AU730224B2 (en) | 1996-12-23 | 2001-03-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US6506757B1 (en) | 1998-03-10 | 2003-01-14 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| MXPA02008801A (es) | 2000-03-09 | 2003-07-07 | Ono Pharmaceutical Co | Derivados de indol, proceso para la preparacion de los mismos y su uso. |
| US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
| US6699997B2 (en) | 2000-06-28 | 2004-03-02 | Teva Pharmaceutical Industries Ltd. | Carvedilol |
| IL153111A0 (en) | 2000-06-30 | 2003-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| ES2272712T3 (es) | 2001-05-23 | 2007-05-01 | Merck Frosst Canada Ltd. | Derivados de dihidropirrolo-1,2-aiindol y tetrahidropirido -1,2-aiindol como antagonistas de receptores de prostaglandina d2. |
| DK1397351T3 (da) | 2001-06-01 | 2010-01-18 | Hoffmann La Roche | Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer |
| HUP0401711A3 (en) | 2001-06-26 | 2009-07-28 | Bristol Myers Squibb Co | N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them |
| JP3968076B2 (ja) | 2001-06-27 | 2007-08-29 | アールエス テック コーポレイション | 新しいキラルサレン化合物、キラルサレン触媒及びこれを利用したラセミックエポキシ化合物からキラル化合物を製造する方法 |
| CA2459515A1 (en) | 2001-09-07 | 2003-03-20 | Kazuhiko Torisu | Indole derivatives |
| DE10148617A1 (de) | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| MXPA04009095A (es) | 2002-03-19 | 2004-12-06 | Ono Pharmaceutical Co | Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo. |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AU2003282679A1 (en) | 2002-10-04 | 2004-05-04 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| EP1551403B1 (en) * | 2002-10-10 | 2009-04-29 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
| DE10261131A1 (de) | 2002-12-20 | 2004-07-01 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| AU2004260636A1 (en) | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases |
| GB0319126D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| GB0319124D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| CA2556073C (en) | 2004-02-14 | 2012-01-10 | Smithkline Beecham Corporation | 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators |
| US20070244107A1 (en) | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| AU2005305086A1 (en) | 2004-11-05 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| WO2006114581A1 (en) | 2005-04-28 | 2006-11-02 | Merck Sharp & Dohme Limited | A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles |
-
2004
- 2004-10-27 PE PE2004001031A patent/PE20050483A1/es not_active Application Discontinuation
- 2004-10-27 TW TW093132486A patent/TWI258478B/zh not_active IP Right Cessation
- 2004-10-28 MY MYPI20044462A patent/MY140410A/en unknown
- 2004-10-29 UA UAA200605989A patent/UA86783C2/ru unknown
- 2004-10-29 GE GEAP20049421A patent/GEP20094801B/en unknown
- 2004-10-29 HR HR20060286T patent/HRP20060286T3/xx unknown
- 2004-10-29 AR ARP040103978A patent/AR046611A1/es unknown
- 2004-10-29 JP JP2006536942A patent/JP4533898B2/ja not_active Expired - Fee Related
- 2004-10-29 US US10/535,345 patent/US8637555B2/en not_active Expired - Fee Related
- 2004-10-29 PL PL04818324T patent/PL1599469T3/pl unknown
- 2004-10-29 DK DK04818324T patent/DK1599469T3/da active
- 2004-10-29 AT AT04818324T patent/ATE328880T1/de active
- 2004-10-29 CN CN2004800299376A patent/CN1867562B/zh not_active Expired - Fee Related
- 2004-10-29 EP EP06005248A patent/EP1683794A1/en not_active Withdrawn
- 2004-10-29 AU AU2004287861A patent/AU2004287861B2/en not_active Ceased
- 2004-10-29 PT PT04818324T patent/PT1599469E/pt unknown
- 2004-10-29 BR BRPI0415631-5A patent/BRPI0415631A/pt not_active IP Right Cessation
- 2004-10-29 WO PCT/US2004/035927 patent/WO2005044816A1/en not_active Ceased
- 2004-10-29 EP EP04818324A patent/EP1599469B1/en not_active Expired - Lifetime
- 2004-10-29 RS YUP-2006/0290A patent/RS20060290A/sr unknown
- 2004-10-29 ES ES04818324T patent/ES2267077T3/es not_active Expired - Lifetime
- 2004-10-29 KR KR1020067008311A patent/KR100850591B1/ko not_active Expired - Fee Related
- 2004-10-29 SI SI200430058T patent/SI1599469T1/sl unknown
- 2004-10-29 MX MXPA06004556A patent/MXPA06004556A/es active IP Right Grant
- 2004-10-29 NZ NZ546285A patent/NZ546285A/en not_active IP Right Cessation
- 2004-10-29 EA EA200600879A patent/EA011484B1/ru not_active IP Right Cessation
- 2004-10-29 CA CA2539985A patent/CA2539985C/en not_active Expired - Fee Related
- 2004-10-29 DE DE602004001134T patent/DE602004001134T2/de not_active Expired - Lifetime
-
2006
- 2006-03-01 IL IL174042A patent/IL174042A0/en unknown
- 2006-03-03 CR CR8270A patent/CR8270A/es not_active Application Discontinuation
- 2006-03-30 CO CO06031620A patent/CO5690551A2/es not_active Application Discontinuation
- 2006-04-28 ZA ZA200603419A patent/ZA200603419B/en unknown
- 2006-04-28 EC EC2006006529A patent/ECSP066529A/es unknown
- 2006-05-22 TN TNP2006000150A patent/TNSN06150A1/en unknown
- 2006-05-23 MA MA29049A patent/MA28171A1/fr unknown
- 2006-05-24 IS IS8481A patent/IS2372B/is unknown
- 2006-05-31 NO NO20062509A patent/NO20062509L/no not_active Application Discontinuation
- 2006-07-26 ZA ZA200606203A patent/ZA200606203B/xx unknown
- 2006-09-05 CY CY20061101259T patent/CY1105479T1/el unknown
- 2006-11-17 US US11/601,252 patent/US20070072924A1/en not_active Abandoned
-
2010
- 2010-03-10 JP JP2010053852A patent/JP2010163448A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20070144A7 (es) | Derivados de pirazol fusionado y métodos de tratamiento de los desórdenes relacionados con el metabolismo | |
| ECSP066529A (es) | Derivados de tetrazol y métodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
| WO2004033431A3 (en) | Hydroxypyrazoles for use against metabolic-related disorders | |
| CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
| UY29384A1 (es) | Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes. | |
| SV2008001369A (es) | Benzimidazoles | |
| CL2009001059A1 (es) | Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras. | |
| ECSP055853A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos | |
| DOP2011000176A (es) | Compuestos organicos | |
| UY31870A (es) | Receptor metabotrópico de glutamato potenciadores 286 | |
| PA8803201A1 (es) | Derivados acidos de cicloalquilamino | |
| ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| UY30736A1 (es) | Compuestos quimicos 537 | |
| ECSP099442A (es) | Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona | |
| UY29893A1 (es) | Derivados de pirazina | |
| ECSP088700A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
| PE20080370A1 (es) | Derivados de quinazolinona como antagonistas de cgrp | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| CR9722A (es) | Derivados de benzilpiperazina y su uso medico | |
| AR069009A1 (es) | Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina | |
| UY29447A1 (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia. | |
| AR056087A1 (es) | Derivados de azetidina como antagonistas de receptores de neuroquina nk | |
| WO2005051937A3 (en) | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof | |
| DOP2005000270A (es) | Derivados funsionados de pirazol y metodos de tratamiento de trastornos metabolicos co estos. |